Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS

Bibliographic Details
Main Authors:	Kalabus, J, Brogan, P, Hofer, M, Kuemmerle-Deschner, J, Lauwerys, B, Speziale, A, Laxer, R, Sun, H, Abrams, K, Leon, K, Junge, G
Format:	Online
Language:	English
Published:	BioMed Central 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597408/

Similar Items

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
by: Brogan, P, et al.
Published: (2015)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
by: Kuemmerle-Deschner, J, et al.
Published: (2015)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
by: Hofer, F, et al.
Published: (2013)

PW02-041 - Canakinumab treatment regimens in CAPS-patients
by: Hofer, F, et al.
Published: (2013)

Canakinumab treat-to target strategies increase complete response rate in CAPS
by: Kuemmerle-Deschner, J, et al.
Published: (2015)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
by: Hansmann, Sandra, et al.
Published: (2011)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
by: Bader-Meunier, B, et al.
Published: (2011)

Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study
by: Aróstegui, JI, et al.
Published: (2015)

P02-027 - Quality of life in CAPS treated by Canakinumab
by: Marsaud, C, et al.
Published: (2013)

PReS-FINAL-2330: Canakinumab treatment in patients with HIDS
by: Antón, J, et al.
Published: (2013)

OR10-006 - Canakinumab in patients with TRAPS
by: Lachmann, HJ, et al.
Published: (2013)

Unmet psychosocial needs in CAPS
by: Erbis, G, et al.
Published: (2015)

Canakinumab treatment in patients with active recurrent or chronic TNF-receptor associated syndrome (TRAPS): Efficacy and safety results from a proof of concept study
by: Lachmann, H, et al.
Published: (2015)

The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)
by: Wittkowski, H, et al.
Published: (2008)

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
by: Kuemmerle-Deschner, Jasmin B, et al.
Published: (2011)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
by: Horneff, G, et al.
Published: (2015)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
by: Kümmerle-Deschner, J, et al.
Published: (2008)

“Daily life of CAPS patients treated with canakinumab (Ilaris®) : data from the French observational study - ENVOL Study”
by: Koné-Paut, I, et al.
Published: (2015)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
by: Caorsi, R, et al.
Published: (2011)

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized
by: Gautier, A, et al.
Published: (2013)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
by: Salugina, Svetlana O, et al.
Published: (2014)

Gene expression profiling in understanding the molecular pathogenesis of and response to canakinumab therapy in traps
by: Gattorno, M, et al.
Published: (2014)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
by: Wulffraat, NM, et al.
Published: (2014)

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
by: Chakraborty, Abhijit, et al.
Published: (2012)

Cervical Lesions in Women Younger than 25 Years
by: Yoleisi Alonso Fleites, et al.
Published: (2011-12-01)

Cervical Lesions in Women Younger than 25 Years
by: Yoleisi Alonso Fleites, et al.
Published: (2011-12-01)

Half-marathoners are younger and slower than marathoners
by: Knechtle, Beat, et al.
Published: (2016)

Clinical experiences with canakinumab as a treatment for autoinflammatory disorders
by: Saperia, C, et al.
Published: (2015)

β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics
by: Kuemmerle-Deschner, J, et al.
Published: (2011)

Adrenocortical tumors in children 18 years old and younger
by: Cho, Min Jeng, et al.
Published: (2012)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
by: Brachat, A, et al.
Published: (2015)

PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis
by: Xiong, Y, et al.
Published: (2013)

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
by: Koné-Paut, Isabelle, et al.
Published: (2011)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
by: Hashkes, PJ, et al.
Published: (2013)

PW01-012 – Canakinumab in patients with FMF
by: Ugurlu, S, et al.
Published: (2013)

P02-008 - Dramatic response to canakinumab in MKD
by: Makay, B, et al.
Published: (2013)

Treatment of systemic-onset juvenile arthritis with canakinumab
by: Peitz, Joachim, et al.
Published: (2015)

Canakinumab therapy in patients with Familial Mediterranean Fever
by: Ugurlu, S, et al.
Published: (2015)

Clinical response to the canakinumab in crohn’s disease related artrhritis
by: Gündüz, Zübeyde, et al.
Published: (2014)

Canakinumab for the treatment of different refractory autoinflammatory disorders
by: Grein, Ingrid HR, et al.
Published: (2014)